Form 4: Kestra Medical CEO Sells Shares Under 10b5-1 Plan
Insider Transaction Report
Kestra Medical Technologies CEO Brian Daniel Webster sold 15,000 common shares for a weighted average price of $26.5898, executed under a pre-arranged 10b5-1 trading plan.
Summary
- Brian Daniel Webster, President and Chief Executive Officer, and a Director of Kestra Medical Technologies, Ltd. (KMTS), reported a transaction.
- On December 29, 2025, Webster disposed of 15,000 common shares at a weighted average price of $26.5898 per share.
- The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on September 29, 2025.
- The selling prices ranged from $26.390 to $26.9504 per share.
- Following this transaction, Webster directly beneficially owns 409,786 common shares.
- The reported beneficial ownership includes 27,209 common shares received from West Affum Holdings, L.P. in a pro rata distribution, which is exempt under Rule 16a-9.
Sentiment
Score: 5
Explanation: The sentiment is neutral. While an insider sale could be viewed negatively, the transaction was conducted under a pre-arranged 10b5-1 trading plan, which indicates it was not based on new, non-public information and is a common practice for executives managing personal finances.
Negatives
- An insider sale, even under a 10b5-1 plan, can sometimes be perceived by investors as a lack of confidence or a signal that the stock may be fully valued.
Future Outlook
This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.
Industry Context
This Form 4 filing reports a routine insider transaction under a pre-arranged trading plan, which is a common practice for executives to manage personal finances and diversify holdings while complying with insider trading regulations. It does not provide specific insights into broader industry trends or competitive landscape.
Stakeholder Impact
- Shareholders may note the reduction in direct ownership by the CEO, though the pre-planned nature of the sale mitigates concerns about immediate market signals.
Key Dates
| Date | Description |
|---|---|
| 09/29/2025 | Adoption date of the Rule 10b5-1 trading plan by Brian Daniel Webster. |
| 12/29/2025 | Date of the reported transaction where 15,000 common shares were sold. |
| 12/31/2025 | Filing date of the Statement of Changes in Beneficial Ownership (Form 4). |
Keywords
Kestra Medical Technologies, KMTS, insider trading, Form 4, stock sale, 10b5-1 plan, CEO, director, equity disposition
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.